The EPS projection of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) for quarter ended 2016-09-30 is $-0.57. Last week, the projection for EPS was $-0.57 against target of $-0.57, a month earlier. While 2-months ago, this projection was $-0.57 versus forecast of $-0.57a quarter months earlier, posting a deviation of 0.26%.
Five Prime Therapeutics, Inc. (NASDAQ:FPRX) posted that 18 days earlier, the share price was revised 1 times on upside. In addition, negative revisions were 1.
In last week, negative EPS revisions were 0 times and positive EPS revisions were 0 times. In last one-month and two month the positive revisions were 0 and 0. While in last 120 and 90 days, positive revisions were 1, and 1, correspondingly.
The per-share earnings downgrade for Five Prime Therapeutics, Inc. (NASDAQ:FPRX) in the preceding 30 and 120 were 0 and 1. While in 60 and 90 days were 0, and 1, in that order.
Five Prime Therapeutics, Inc. (NASDAQ:FPRX) EPS target was $-0.57 for the quarter closed 1. It was based on 4 calls. As on 2016-05-05 the EPS was $-0.49. The change was $0.14, posting a deviation of 22.22%. The price projections gave a standard deviation of 0.36.
Quarterly Sales Estimates
Five Prime Therapeutics, Inc. (NASDAQ:FPRX) sales prediction for the fiscal 2016 stands at $5.615 and the median estimate is at $5.615. Almost 2 analysts gave sales target.
Among this, the highest sales estimate is $7.1 while the lowest target is $4.13 showing standard deviation of 2.1%.
As many as 2 analysts have positive sales targets revision while 2 reduced sales estimates, posting a deviation of -35.777%.
Last month, 2 experts have positive sales number revision. Also, 2 research groups lowered the sales projections, posting a deviation of -35.777%.
A quarter ago, 2 hiked sales target and 2 reduced sales forecast, posting a deviation of -47.733%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...